Normalization of Fecal Calprotectin Within 12 Months of Diagnosis is Associated with Reduced Risk of Disease Progression in Patients with Crohn ’s Disease

The level of fecal calprotectin (FC) correlates with endoscopic evidence of inflammation in Crohn ’s disease (CD). A treat-to-target algorithm for patients with CD, that incorporates FC, outperforms a treatment strategy based on symptoms alone in induction of mucosal healing at 12 months. We investigated whether normalization of FC within 12 months of diagnosis of CD is associated with a reduc tion in disease progression.

Source: Clinical Gastroenterology and Hepatology - August 11, 2020 Category: Gastroenterology Authors: N. Plevris, J. Fulforth, M. Lyons, S.I. Siakavellas, P.W. Jenkinson, C.S. Chuah, Laura Lucaciu, R.J. Pattenden, I.D. Arnott, G.R. Jones, C.W. Lees Source Type: research